AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

One of the last big pharma holdouts in obesity has now entered what has become the most sought-after field in the industry. AbbVie said Monday morning it's making the leap into the obesity field for ...

Mar 3, 2025 - 09:57

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

One of the last big pharma holdouts in obesity has now entered what has become the most sought-after field in the industry. AbbVie said Monday morning it's making the leap into the obesity field for ...